STOCK TITAN

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences earnings

Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its upcoming second quarter and first half 2024 financial results conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET. Management will present the financial results and provide a corporate update during the call.

Investors and interested parties can access the live audio webcast by registering at the provided link. The webcast will also be archived and available for one year in the Investors section of the Iovance website. This event offers an opportunity for stakeholders to gain insights into the company's financial performance and recent developments in its innovative cancer therapies.

Iovance Biotherapeutics (NASDAQ: IOVA), un'azienda biotecnologica specializzata in nuove terapie con linfociti infiltranti tumorali (TIL) per i pazienti affetti da cancro, ha annunciato la sua prossima conferenza telefonica sui risultati finanziari del secondo trimestre e del primo semestre del 2024. L'evento è previsto per giovedì 8 agosto 2024, alle 16:30 ET. La direzione presenterà i risultati finanziari e fornirà un aggiornamento aziendale durante la chiamata.

Investitori e parti interessate possono accedere alla trasmissione audio in diretta registrandosi attraverso il link fornito. La trasmissione sarà anche archiviata e disponibile per un anno nella sezione Investitori del sito web di Iovance. Questo evento offre un'opportunità agli stakeholder per ottenere informazioni sulle prestazioni finanziarie dell'azienda e sui recenti sviluppi delle sue innovative terapie contro il cancro.

Iovance Biotherapeutics (NASDAQ: IOVA), una empresa biotecnológica especializada en nuevas terapias con linfocitos infiltrantes tumorales (TIL) para pacientes con cáncer, ha anunciado su próxima conferencia telefónica sobre los resultados financieros del segundo trimestre y del primer semestre de 2024. El evento está programado para jueves 8 de agosto de 2024, a las 4:30 p.m. ET. La dirección presentará los resultados financieros y proporcionará una actualización corporativa durante la llamada.

Los inversores y partes interesadas pueden acceder a la transmisión de audio en vivo registrándose en el enlace proporcionado. La transmisión también será archivada y estará disponible durante un año en la sección de Inversores del sitio web de Iovance. Este evento ofrece una oportunidad para que las partes interesadas obtengan información sobre el rendimiento financiero de la empresa y los desarrollos recientes en sus innovadoras terapias contra el cáncer.

Iovance Biotherapeutics (NASDAQ: IOVA)는 암 환자를 위한 새로운 다기관 종양 침투 림프구(TIL) 치료를 전문으로 하는 생명공학 회사입니다. 이 회사는 2024년 2분기 및 상반기 재무 결과에 대한 컨퍼런스 콜을 곧 개최할 예정임을 발표했습니다. 이번 이벤트는 2024년 8월 8일 목요일 오후 4시 30분 ET로 예정되어 있습니다. 경영진은 통화 중에 재무 결과를 발표하고 회사 업데이트를 제공할 것입니다.

투자자 및 관심 있는 당사자는 제공된 링크를 통해 라이브 오디오 웹캐스트에 등록하여 접근할 수 있습니다. 이 웹캐스트는 또한 아카이브되어 Iovance 웹사이트의 투자자 섹션에서 1년 동안 이용 가능합니다. 이 이벤트는 이해관계자에게 회사의 재무 성과 및 혁신적인 암 치료에 대한 최근 개발 정보를 얻을 수 있는 기회를 제공합니다.

Iovance Biotherapeutics (NASDAQ: IOVA), une entreprise biopharmaceutique spécialisée dans les nouvelles thérapies par lymphocytes infiltrants tumoraux (TIL) pour les patients atteints de cancer, a annoncé sa prochaine conférence téléphonique sur les résultats financiers du deuxième trimestre et du premier semestre 2024. L'événement est prévu pour jeudi 8 août 2024, à 16h30 ET. La direction présentera les résultats financiers et fournira une mise à jour de l'entreprise pendant l'appel.

Les investisseurs et les parties intéressées peuvent accéder à la diffusion audio en direct en s'inscrivant via le lien fourni. La diffusion sera également archivée et disponible pendant un an dans la section Investisseurs du site web d'Iovance. Cet événement offre une opportunité aux parties prenantes d'obtenir des informations sur la performance financière de l'entreprise et les développements récents de ses thérapies innovantes contre le cancer.

Iovance Biotherapeutics (NASDAQ: IOVA), ein Biotechnologieunternehmen, das auf neuartige polyklonale tumorinfiltrierende Lymphozyt (TIL) Therapien für Krebspatienten spezialisiert ist, hat seine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen des zweiten Quartals und der ersten Hälfte 2024 angekündigt. Die Veranstaltung ist für Donnerstag, den 8. August 2024, um 16:30 Uhr ET angesetzt. Das Management wird die finanziellen Ergebnisse präsentieren und während des Anrufs ein Unternehmensupdate geben.

Investoren und Interessierte können auf die Live-Audioübertragung zugreifen, indem sie sich über den bereitgestellten Link registrieren. Die Übertragung wird auch archiviert und ist ein Jahr lang im Investor-Bereich der Iovance-Website verfügbar. Diese Veranstaltung bietet den Stakeholdern die Möglichkeit, Einblicke in die finanzielle Leistung des Unternehmens und aktuelle Entwicklungen in seinen innovativen Krebstherapien zu gewinnen.

Positive
  • None.
Negative
  • None.

SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year. 

AboutIovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control.

CONTACTS

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com

Jen Saunders
Senior Director, Investor Relations & Corporate Communications
267-485-3119
Jen.Saunders@iovance.com


FAQ

When will Iovance Biotherapeutics (IOVA) report its Q2 and H1 2024 financial results?

Iovance Biotherapeutics (IOVA) will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024.

What time is Iovance Biotherapeutics' (IOVA) Q2 2024 earnings call scheduled?

Iovance Biotherapeutics' (IOVA) Q2 2024 earnings conference call and webcast is scheduled for 4:30 p.m. ET on Thursday, August 8, 2024.

How can investors access Iovance Biotherapeutics' (IOVA) Q2 2024 earnings webcast?

Investors can access Iovance Biotherapeutics' (IOVA) Q2 2024 earnings webcast by registering at https://edge.media-server.com/mmc/p/uhudv42k/ or through the Investors section of the company's website, IR.Iovance.com.

What is Iovance Biotherapeutics' (IOVA) main focus in cancer treatment?

Iovance Biotherapeutics (IOVA) focuses on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

IOVA Rankings

IOVA Latest News

IOVA Stock Data

2.23B
276.35M
0.58%
88.54%
17.71%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN CARLOS